Table 1 Patient demographics of training and validation cohorts of the PANGEA project to integrate dynamic biomarkers into progression risk prediction for patients with SMM
From: Enhanced dynamic risk stratification of smoldering multiple myeloma
Training (n = 1,031) | Validation 1 (n = 485) | Validation 2 (n = 447) | Validation 3 (n = 240) | Validation 4 (n = 67) | Validation 5 (n = 74) | |
|---|---|---|---|---|---|---|
Age at diagnosis (years) – median (IQR) | 61.7 (53.3−69.0) | 63.8 (54.0−72.9) | 60.0 (52.0−67.0) | 66.0 (58.0−74.3) | 67.7 (58.5−76.6) | 60.5 (50.5−67.0) |
Clinical laboratory visits – median (IQR) | 4 (2−8) | 5 (3−8) | 5 (2 −10) | 3 (1−5) | 7 (4−11) | 1 (1−3) |
Follow up (years) – median (IQR) | 3.7 (1.8−7.1) | 5.3 (3.0−9.7) | 3.4 (1.4−6.3) | 1.6 (0.7−2.7) | 3.4 (2.3−6.4) | 6.4 (2.2−10.8) |
Time between visits (months) – median (IQR) | 6.0 (3.7−7.6) | 5.5 (3.4−8.5) | 3.9 (3.0−6.2) | 6.0 (4.0−6.7) | 4.1 (3.4−4.9) | 13.6 (8.5−25.7) |
Sex – n (%) | ||||||
Female | 504 (49%) | 278 (58%) | 196 (44%) | 122 (51%) | 30 (45%) | 34 (46%) |
Male | 527 (51%) | 206 (42%) | 251 (56%) | 118 (49%) | 37 (55%) | 40 (54%) |
Race – n (%) | ||||||
Asian | 26 (3%) | 17 (4%) | 1 (1%) | |||
Black | 86 (8%) | 19 (4%) | 1 (1%) | |||
White | 882 (86%) | 429 (88%) | 66 (99%) | 73 (99%) | ||
Not available | 37 (4%) | 19 (4%) | 447 (100%) | 240 (100%) | ||
MM progressor – n (%) | ||||||
No | 800 (78%) | 326 (67%) | 307 (69%) | 181 (75%) | 40 (60%) | 38 (51%) |
Yes | 231 (22%) | 159 (33%) | 140 (31%) | 59 (25%) | 27 (40%) | 36 (49%) |
Immunofixation – n (%) | ||||||
Biclonal | 7 (1%) | 7 (1%) | 8 (2%) | 48 (20%) | 1 (1%) | |
IgA | 236 (6%) | 123 (25%) | 114 (26%) | 63 (26%) | 16 (24%) | 21 (28%) |
IgG | 723 (70%) | 338 (70%) | 303 (68%) | 123 (51%) | 48 (72%) | 46 (62%) |
Light chain only | 62 (6%) | 12 (2%) | 16 (4%) | 1 (1%) | ||
Not available | 10 (1%) | 5 (1%) | 1 (0%) | 6 (3%) | 7 (10%) | |
Censored due to – n (%) | ||||||
Death | 22 (2%) | 12 (2%) | 16 (4%) | 12 (5%) | ||
Early intervention | 233 (23%) | 5 (1%) | 16 (4%) |
